225Actinium-armed antibody targeting CCR8+ regulatory T cells synergizes with immunotherapy to promote tumor rejection in syngeneic colorectal cancer models
These data demonstrate a synergistic effect of anti-aCCR8 RIT with immunotherapy through enhancement of adaptive and innate anti-tumor responses. Further investigation of anti-CCR8 RIT as a potential cancer-agnostic agent and its combinations with other immunotherapy agents such as anti-PD-1, LAG3 or TIGIT is warranted.
Authors
- Zhiwen Xiao (ORCID: https://orcid.org/0000-0001-8640-2067)
- Connor Frank (ORCID: https://orcid.org/0000-0002-2910-9857)
- Ekaterina Dadachova (ORCID: https://orcid.org/0000-0001-7300-6479)
- Kevin J. Allen (ORCID: https://orcid.org/0000-0002-6019-472X)
- Mackenzie E. Malo (ORCID: https://orcid.org/0000-0002-9118-0806)
- Rubin Jiao
Institutions
- University of Saskatchewan (CA)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-09-16
- DOI
- https://doi.org/10.3389/fimmu.2025.1662216
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Colorectal Cancer Alliance
- College of Pharmacy and Nutrition, University of Saskatchewan